FUNDAMENTALS · Fundamentals · SG Healthcare

Thomson Medical Group (A50) Fundamentals 2026 — Revenue Analysis | SniperIQ

Thomson Medical Group (A50) is a SG-listed Healthcare company in Medical - Care Facilities with a market capitalization of S

.4B, trading at S$0.05 on the SES. This SniperIQ fundamentals page covers Thomson Medical Group's valuation, profitability (net margin -9.6%), revenue (S
95M in FY2024), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapS
.4B
Net Margin-9.6%
Revenue (FY24)S
95M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Thomson Medical Group's market cap?

Thomson Medical Group (A50) has a market capitalization of approximately S

.4B, trading at S$0.05 on the SES. Market cap moves with the live share price.

What is Thomson Medical Group's P/E ratio?

Thomson Medical Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Thomson Medical Group?

Thomson Medical Group runs a net profit margin of -9.6%, a gross margin of 47.0%, and an operating margin of 3.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Thomson Medical Group generate?

Thomson Medical Group reported revenue of S

95M for fiscal year 2024, with net income of -S$48M and earnings per share (EPS) of -0.0018. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Thomson Medical Group pay a dividend?

Thomson Medical Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Thomson Medical Group financially healthy?

Thomson Medical Group carries a debt-to-equity ratio of 2.29x and a current ratio of 2.37x, with a market beta of 0.28. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Thomson Medical Group a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Thomson Medical Group (A50) the key facts are: market cap S

.4B, revenue S
95M, 52-week range 0.045-0.068. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Thomson Medical Group's full fundamentals live

Get Thomson Medical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: ArriVent BioPharma (AVBP) fundamentals · Taysha Gene Therapies (TSHA) fundamentals · The Pennant Group (PNTG) fundamentals · Absci (ABSI) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons